Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?

Empagliflozin’s Fuel Hypothesis: Not so Soon

(2016) Gary D. Lopaschuk et al.   Cell Metabolism

SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study

(2016) Muhammad Abdul-Ghani et al.   DIABETES CARE

Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?

(2016) Subodh Verma et al.   DIABETES CARE

CV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis

(2016) Ele Ferrannini et al.   DIABETES CARE

SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?

(2016) Naveed Sattar et al.   DIABETOLOGIA

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Zebrafish Heart Failure Models for the Evaluation of Chemical Probes and Drugs

(2013) Cheng-Chen Huang et al.   ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES

In vivo natriuretic peptide reporter assay identifies chemical modifiers of hypertrophic cardiomyopathy signalling

(2011) Jason R. Becker et al.   CARDIOVASCULAR RESEARCH